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receiver operating characteristic curve (ROC) analysis to 
define the cut-off points for significant parameters.  
Results: Median follow-up time was 20.5 months (range 4 – 
91) and 18 months (14-80) for primary and secondary lung 
cancer. RP G1-2 has been observed in 23/54 patients 
(42.59%); no pulmonary toxicity >G2 has occurred, as there 
has been no toxicity of controlateral lung and other organs at 
risk. Univariate statistical analysis showed that 
GTV(p=0.036), PTV (p=0.022), MLD (p=0.003) and V5 
(p=0.002), V10 (p=0.002), V20 (p=0.012), V30 (p=0.002) were 
significant variables for the risk of developing RP. 
Multivariate statistical analysis has found that the predictor 
variables of RP are V5 (p=0.004), V10 (p=0.009), V20 
(p=0.014), V30 (p=0.007) and the MLD (p=0.011). The 
greatest risk was connected to the variable V30 (HR 1.985 ).  
On the ROC curve, the cut-off values of ipsilateral lung 
V5,V10,V20,V30 and MLD were 29.50%,19.50%,9.55%,4.58% 
and 4.7%, respectively (Fig.1). A cutoff of 4.58% for V30 had 
a sensitivity of 80% and specificity of 82.1%. 
 
Conclusions: In our study stereotactic body radiotherapy was 
well tolerated for primary and secondary lung cancer 
treatment. V5, V10, V20, V30 and MLD were significantly 
predictive of RP.  
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Purpose/Objective: Analyse clinical and dosimetric results of 
helical tomotherapy (HT) and rapidarc (RA) in complex 
adjuvant breast and nodes (IMC and supraclavicular nodes) 
irradiation with simultaneous-integrated boost. 
Materials and Methods: Seventy-nine patients were included 
in the study (37 HT and 42 RA). Treatments were in 29 
fractions. Dose prescriptions were 63.8 Gy (HT) and 63.2 Gy 
(RA) in the tumour bed, 52.2 Gy in the breast (HT and RA), 
50.4 Gy in supraclavicular nodes and IMC with HT and 52.2 Gy 
and 49.3 Gy in IMC and supraclavicular nodes with RA. 
Margins to the PTV were larger in the rapidarc group (7mm vs 
5mm). 
Results: For HT cohort, the coverage of clinical target 
volumes (CTV) was as follows: CTV tumour bed: 99,4%±2,4; 
CTV breast: 98,4%±4,3; CTV supraclavicular nodes: 
99,5%±1.2; CTV IMC: 96,5%±13,9. For RA cohort, the coverage 
of CTV was as follows: CTV tumour bed: 99,7%%±0,5, CTV 
breast: 99,3 %±0,7; CTV supraclavicular nodes: 99,6%±1,4; 
CTV IMC: 99,3%±3. For ipsilateral lung, Dmean and V20 were 
13, 5 Gy±1, 4, 20,9%±4,9 (HT) and 13,6 Gy±1,4, 20,1%±3,2 
(RA). Dmean and V30 of the heart were 7,4 Gy±1,4, 1%±1 
(HT) and 10,3 Gy±4,2, 2,5%±3,9 (RA). For controlateral breast 
Dmean was 3, 6 Gy±0,7 (HT) and 4,6 Gy±0,9 (RA). There was 
5% of acute skin toxicity grade ≥ 3 in the two cohorts and 35% 
of oesophageal toxicity grade≤ 2 in HT and 40% in RA. 
Conclusions: Rotational IMRT in complex adjuvant breast and 
nodes irradiation allows a good coverage of target volumes 
with an acceptable acute tolerance. A longer follow-up is 
needed to assess the impact of low doses to healthy 
tissues
 
Breast irradiation with HT in a patient with funnel chest 
(isodose 45 Gy) 
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Purpose/Objective: To investigate the feasibility and 
tolerance in the use of adjuvant Intensity Modulated 
Radiation Therapy (IMRT) and simultaneous integrated boost 
(SIB) in patients with a diagnosis of breast cancer after 
breast-conserving surgery (BCS). 
Materials and Methods: Between September 2011 to 
February 2013, 150 women with a diagnosis of breast cancer 
were treated with SIB-IMRT after BCS in our Institution. A 
dose prescription of 50 Gy in 25 fractions was prescribed to 
the whole breast (PTVbreast) and an additional dose of 
radiation on the tumour bed was prescribed (PTVboost). A 
dose prescription of 60 Gy in 25 fractions to PTVboost was 
used in patients with negative margins after surgery, whereas 
if the margins were close (< 1 mm) or positive (without a new 
surgical resection) a dose of 64 Gy was prescribed. All 
patients were followed with periodic clinical evaluation. 
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Acute and late toxicity were scored using the EORTC/RTOG 
radiation morbidity score system. Both patient and physician 
recorded cosmetic outcome evaluation with a subjective 
judgment scale at the time of scheduled follow-up. 
Results: The median follow-up was 24 months (range 19 - 36 
months). The acute skin grade toxicity during the treatment 
was G0 in 10 patients (6.7%), G1 in 105 (70%), G2 in 35 cases 
(23.3%). No grade 3 or higher acute skin toxicity was 
observed. At 12 months, skin toxicity was G0 in 105 (70%), G1 
in 45 (30%). No toxicity ≥ G2 was registered. At 24 months 
skin toxicity was G0 in 130 (86%), G1 in 20 (14%). No case ≥ 
G2 was registered.  
The pre-treatment variables correlated with skin grade G2 
acute toxicity were adjuvant chemotherapy (p=0.01) and 
breast volume ≥ 700 cm3 (p= 0.001). Patients with an acute 
skin toxicity grade 2 had a higher probability to develop late 
skin toxicity (p<0.0001). In the 98% of cases, patients were 
judged to have a good or excellent cosmetic outcome. The 2-
year-Overall Survival and 2-year-Local Control were 100%. 
Conclusions: These data support the feasibility and safety of 
SIB-IMRT in patients with a diagnosis of breast cancer 
following BCS with acceptable acute and late treatment-
related toxicity. A longer follow-up is needed to define the 
efficacy on outcomes. 
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Purpose/Objective: To determine individual variability of 
axillary sentinel lymph nodes (SLN) localization in patient 
with breast cancer (BC) and to evaluate clinical value of 
SPECT-CT with radiocolloids for field design and treatment 
planning 
Materials and Methods: Individual topography of axillary SLN 
was determined in 127 patients with early BC. All women 
were candidates for conservative surgical treatment with 
postoperative radiotherapy. SPECT-CT visualization of SLN 
started 120-240 min after intratumoral injection of 74-
150MBq of 99mTc-radiocolloids. Distribution of axillary SLN 
was allocated to following subregions: central (C), anterior 
pectoral (AP), sub-(SP) intrapectoral (IP), lateral (L), 
subscapular (SSc), LN 'lying on the ribs' (Th).  
During the second part of the study we used routine 3D plans 
for standard tangential fields and contoured on this plans SLN 
of each axillary subregion. The same procedure was repeated 
for individually shaped extended tangential fields with upper 
border on the lower border of the humeral head. At the end, 
for SLN localized in Th subregion we tested intensity 
modulated radiation therapy (IMRT) treatment plans 
Results: SPECT-CT visualization of SLN demonstrated large 
variability in their localization. In most cases they were 
detected in C (64 observations, 50.5%) and AP (34 women, 
26.8%) subregions. In 19 (14.9%) cases SLN were revealed in 
Th and in another 10 (7.8%) patients –in L or SSc subregions. 
In 17 (13.4%) women SLN were localized both on I and II (IP, 
SP) levels. 
3D modeling of dose distribution obtained with different 
radiotherapy techniques help us to evaluate coverage of SLN 
localized in various axillary subregions. We found that our 
standard tangential fields do not cover SLN in 80% cases. In 
20% they encompass C, AP, IP, SP nodes. Slight modification 
of tangential fields permit effective irradiation of C, AP, IP, 
SP, L, SSc nodes in all cases. Th LN can be covered only with 
the help of IMRT 
Conclusions: SPECT-CT localization of SLN is an important 
part of radiotherapy planning in patients with early BC. 
SPECT-CT results advocate application of standard tangential 
fields in 20%, extended tangential fields – in 65.1% and IMRT – 
in remained 14.9% of evaluated patients  
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Purpose/Objective: Breast cancer radiotherapy has been 
associated with an increased risk of coronary disease. 
According to literature the amount of calcium deposits in the 
coronary arteries (CAC scores) predicts the risk of subsequent 
cardiovascular events, even without symptomatic Coronary 
Artery Disease [Greenland 2007; Oudkerk 2008; Kavousi 
2012]. However, no data are available on the amount of 
Coronary Artery Calcium (CAC) in the coronary arteries 
before and after radiotherapy for breast cancer. Therefore, 
CAC scores were prospectively determined to identify 
differences in CAC scores between three groups of breast 
cancer patients by comparing them before the start of 
radiotherapy and three years after radiotherapy.  
Materials and Methods: Ninety-nine consecutive patients 
with breast cancer referred for radiotherapy after breast 
conserving surgery were included in our study. Their 
cardiovascular risk-profile was registered, and 64multi-slice 
CT-scans were performed at baseline and three years after 
radiotherapy. 
The patients were subdivided in three groups: left- and right-
sided radiotherapy, and left-sided radiotherapy using a 
breath-hold technique. The differences in increase of the 
overall and Left Anterior Descending (LAD) CAC scores were 
determined. Within each patient also LAD-RCA scores were 
analyzed, representing CAC scores of the LAD coronary artery 
minus those of the Right Coronary Artery (RCA). 
Results: After three years, a non-significant lower increase in 
overall CAC scores and a significant lower increase in mean 
CAC scores in the LAD was found for the group with left-sided 
breast cancer treated with breath-hold compared to the 
group without breath-hold. Furthermore, the LAD-RCA scores 
